Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women
Abstract
OBJECTIVE: To determine the effects of metformin on blood pressure, left ventricular mass, and some metabolic and endocrine parameters in nondiabetic, obese, hypertensive women. RESEARCH DESIGN AND METHODS: Twelve obese, nondiabetic, hypertensive women received 850 mg metformin 2 times/day for 12 wk and placebo for another 12 wk, according to a double-blind, cross-over, randomized design. All patients were hospitalized 4 times, i.e., before randomization and after each treatment (metformin or placebo), to conduct metabolic and cardiovascular investigations (oral glucose tolerance test, euglycemic clamp associated with indirect calorimetry, and echocardiography). RESULTS: Fasting glucose, HbA1c, fasting and glucose-stimulated insulin, blood pressure and left ventricular mass, cholesterol, triglycerides, and fibrinogen decreased significantly after metformin treatment, whereas high-density lipoprotein cholesterol increased. The improvement in glucose metabolism resulted from increased sensitivity to insulin. CONCLUSIONS: These findings suggest that metformin treatment in obese, nondiabetic, hypertensive women produces a more favorable cardiovascular risk profile.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Hypoglycemia is very uncommon with metformin monotherapy but has been reported in combination regimens, likely due to metformin potentiating other therapeutic agents.
“Hypoglycemia is very uncommon with metformin monotherapy [173] but has been reported in combination regimens [174], likely due to metformin potentiating other therapeutic agents.”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [173]
Cited by
Sorted by citations
Kim, J.-A., Montagnani, M., Koh, K. K., & Quon, M. J. (2006) · Circulation · doi:10.1161/circulationaha.105.563213 · Cited by 1,652 · see citing works
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,345 · see citing works
Cardiovascular Actions of Insulin
Muniyappa, R., Montagnani, M., Koh, K. K., & Quon, M. J. (2007) · Endocrine Reviews · doi:10.1210/er.2007-0006 · Cited by 873 · see citing works
Zeng, G., & Quon, M. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118871 · Cited by 726 · see citing works
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567 · see citing works
“Hypoglycemia is very uncommon with metformin monotherapy [173] but has been reported in combination”
BackgroundStettler, C., Allemann, S., Jüni, P., Cull, C. A., Holman, R. R., Egger, M., Krähenbühl, S., & Diem, P. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.09.015 · Cited by 468 · see citing works
Freemark, M., & Bursey, D. (2001) · PEDIATRICS · doi:10.1542/peds.107.4.e55 · Cited by 432 · see citing works
Cusi, K. J., Consoli, A., & DeFronzo, R. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.11.8923861 · Cited by 456 · see citing works
Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T., Finck, B. N., Patterson, B. W., Horton, J. D., Mittendorfer, B., Hotamışlıgil, G. S., et al. (2010) · Diabetes · doi:10.2337/db10-0308 · Cited by 400 · see citing works
“, metformin and thiazolidinediones) (34-41).”
BackgroundDunn, C. J., & Peters, D. H. (1995) · Drugs · doi:10.2165/00003495-199549050-00007 · Cited by 391 · see citing works
Pathophysiology and Pharmacological Treatment of Insulin Resistance
Matthaei, S., Stümvoll, M., Kellerer, M., & Häring, H. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 372 · see citing works
Hundal, R. S., & Inzucchi, S. E. (2003) · Drugs · doi:10.2165/00003495-200363180-00001 · Cited by 312 · see citing works
Bangalore, S., Parkar, S., Grossman, E., & Messerli, F. H. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.05.057 · Cited by 290 · see citing works
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S. L., Nicholls, A. W., Baker, D., Horn, S. V., Thomas, E., Rajpal, D. K., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 285 · see citing works
“In addition, metformin improves the lipid profile [4], restores ovarian function in polycystic ovary syndrome [5], reduces fatty infiltration of the liver [6], and lowers microvascular and macrovascular complications associated with T2DM.”
BackgroundAn Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus
Davidson, M. B., & Peters, A. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(96)00353-1 · Cited by 252 · see citing works
Meta-analysis: metformin treatment in persons at risk for diabetes mellitus
Salpeter, S. R., Buckley, N. S., Kahn, J. A., & Salpeter, E. E. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.09.016 · Cited by 248 · see citing works
Nesti, L., & Natali, A. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.04.009 · Cited by 211 · see citing works
A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus
Howlett, H. C. S., & Bailey, C. J. (1999) · Drug Safety · doi:10.2165/00002018-199920060-00003 · Cited by 199 · see citing works
“[134,135] Metformin has also been shown to improve erythrocyte deformability,[136] and enhance limb blood flow in patients with type 2 diabetes mellitus[39] and during leg plethysmography studies in patients with peripheral vascular disease,[40,41] although claims of lowered blood pressure in some studies[29,30] have…”
BackgroundThe Importance of Hyperglycemia in the Nonfasting State to the Development of Cardiovascular Disease
Haffner, S. M. (1998) · Endocrine Reviews · doi:10.1210/edrv.19.5.0343 · Cited by 193 · see citing works
Combination of Insulin and Metformin in the Treatment of Type 2 Diabetes
Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Ogterop, J. C., van der Burg, B. B., Donker, A. J. M., & Stehouwer, C. D. A. (2002) · Diabetes Care · doi:10.2337/diacare.25.12.2133 · Cited by 174 · see citing works
Can metformin reduce insulin resistance in polycystic ovary syndrome?
Açbay, Ö., & Gündoğdu, S. (1996) · Fertility and Sterility · doi:10.1016/s0015-0282(16)58266-1 · Cited by 173 · see citing works
Goodarzi, M. O., & Bryer‐Ash, M. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00448.x · Cited by 160 · see citing works
Wang, C., Niederstrasser, H., Douglas, P. M., Lin, R., Jaramillo, J., Li, Y., Oswald, N. W., Zhou, A., McMillan, E. A., Mendiratta, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-02332-3 · Cited by 156 · see citing works
Metformin‐associated lactic acidosis: a rare or very rare clinical entity?
Chan, N. N., Brain, H. P. S., & Feher, M. D. (1999) · Diabetic Medicine · doi:10.1046/j.1464-5491.1999.00006.x · Cited by 138 · see citing works
Agard, C., Rolli‐Derkinderen, M., de la Roque, E. D., Rio, M., Sagan, C., Savineau, J., Loirand, G., & Pacaud, P. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00445.x · Cited by 128 · see citing works
“Furthermore, metformin is described to have anti-hypertensive properties in hypertensive obese women and in patients with type 2 diabetes (Giugliano et al., 1993).”
BackgroundMetformin Beyond Diabetes: Pleiotropic Benefits of Metformin in Attenuation of Atherosclerosis
Forouzandeh, F., Salazar, G., Patrushev, N. A., Xiong, S., Hilenski, L. L., Fei, B., & Alexander, R. W. (2014) · Journal of the American Heart Association · doi:10.1161/jaha.114.001202 · Cited by 127 · see citing works
“Also, data from clinical studies confirm a modest effect of metformin on attenuation of blood pressure.(54) However, data are scarce on whether cardiovascular benefits of metformin can be seen in nondiabetic conditions such as in patients with risk factors for CVD in the absence of DM2.”
BackgroundWorldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis
Campbell, I. W., & Howlett, H. C. S. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110509 · Cited by 122 · see citing works
Metabolic consequences of hyperglycemia and insulin resistance
Jellinger, P. S. (2007) · Clinical cornerstone · doi:10.1016/s1098-3597(07)80019-6 · Cited by 121 · see citing works
Treatment of Obesity Hypertension and Diabetes Syndrome
Zanella, M. T., Kohlmann, O., & Ribeiro, A. B. (2001) · Hypertension · doi:10.1161/01.hyp.38.3.705 · Cited by 119 · see citing works
Majithiya, J. B., & Balaraman, R. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.10.020 · Cited by 114 · see citing works
Mittendorfer, B., Horowitz, J. F., DePaoli, A. M., Mccamish, M. A., Patterson, B. W., & Klein, S. (2011) · Diabetes · doi:10.2337/db10-1302 · Cited by 114 · see citing works
“In contrast, current treatment strategies for insulin resistance, such as weight loss and pharmacotherapy, improve insulin-mediated glucose uptake by ;25% or more (13,26,27).”
BackgroundMetformin: a new oral biguanide
Campbell, R. K., White, J. R., & Saulie, B. A. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80017-8 · Cited by 113 · see citing works
Role of Metformin for Weight Management in Patients Without Type 2 Diabetes
Desilets, A. R., Dhakal-Karki, S., & Dunican, K. C. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k656 · Cited by 111 · see citing works
Mean HbA1c and mortality in diabetic individuals with heart failure: a population cohort study
Elder, D. H. J., Singh, J. S. S., Levin, D., Donnelly, L. A., Choy, A.-M., George, J., Struthers, A. D., Doney, A. S. F., & Lang, C. C. (2016) · European Journal of Heart Failure · doi:10.1002/ejhf.455 · Cited by 109 · see citing works
Cho, E. J., Hwang, H. J., Kim, S. W., Oh, J. Y., Baek, Y. M., Choi, J. W., Bae, S. H., & Yun, J. W. (2007) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-007-0972-2 · Cited by 108 · see citing works
“Among these, metformin (a biguanide) and thiazolidinediones (TZDs) have proven to be quite useful (Bailey and Turner 1996; Giugliano et al. 1993; Landin et al. 1991; Lee et al. 1994; Verma et al. 1994).”
BackgroundEffect of the anti-diabetic drug metformin on bone mass in ovariectomized rats
Gao, Y., Li, Y., Xue, J., Jia, Y., & Hu, J. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.02.051 · Cited by 105 · see citing works
Metformin as Treatment for Overweight and Obese Adults: A Systematic Review
Levri, K. M. (2005) · The Annals of Family Medicine · doi:10.1370/afm.343 · Cited by 104 · see citing works
Cheng, Y., Leu, H., Chen, T., Chen, C.-L., Kuo, C., Lee, S., & Kao, C.-L. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.09.001 · Cited by 104 · see citing works
Montagnani, M., & Quon, M. J. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00092.x · Cited by 102 · see citing works
Nyane, N. A., Tlaila, T. B., Malefane, T. G., Ndwandwe, D. E., & Owira, P. M. O. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.03.042 · Cited by 101 · see citing works
Reddy, K. J., Singh, M., Bangit, J. R., & Batsell, R. R. (2010) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0b013e328333645a · Cited by 99 · see citing works
Manohar, V., Talpur, N. A., Echard, B. W., et al. (2002) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2002.00180.x · Cited by 99 · see citing works
Inhibitory effect of metformin on intestinal glucose absorption in the perfused rat intestine
Ikeda, T., Iwata, K., & Murakami, H. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00396-2 · Cited by 94 · see citing works
The triglyceride–high-density lipoprotein axis: An important target of therapy?
Szapary, P. O., & Rader, D. J. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.03.037 · Cited by 87 · see citing works
Malin, S. K., Nightingale, J., Choi, S., Chipkin, S. R., & Braun, B. (2013) · Obesity · doi:10.1002/oby.20235 · Cited by 88 · see citing works
“BP is often lowered after exercise training (11), but the effects of metformin are less consistent (13,29-31).”
BackgroundGuðbjörnsdóttir, S., Friberg, P., Elam, M., Attvall, S., Lönnroth, P., & Wallin, B. G. (1994) · Blood Pressure · doi:10.3109/08037059409102293 · Cited by 80 · see citing works
Amador‐Licona, N., Guízar-Mendoza, J., Vargas, E., Sánchez-Camargo, G., & Zamora-Mata, L. (2000) · Archives of Medical Research · doi:10.1016/s0188-4409(00)00241-1 · Cited by 78 · see citing works
Exercise in a Pill: The Latest on Exercise-Mimetics
Guerrieri, D., Moon, H. Y., & van Praag, H. (2016) · Brain Plasticity · doi:10.3233/bpl-160043 · Cited by 77 · see citing works
Metformin: Intrinsic Vasculoprotective Properties
Wiernsperger, N. F. (2000) · Diabetes Technology & Therapeutics · doi:10.1089/15209150050025230 · Cited by 75 · see citing works
SPHK1 Is a Novel Target of Metformin in Ovarian Cancer
Hart, P. C., Chiyoda, T., Liu, X., Weigert, M., Curtis, M., Chiang, C.-Y., Loth, R. M., Lastra, R. R., McGregor, S. M., Locasale, J. W., et al. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0409 · Cited by 73 · see citing works
“The biguanide metformin has been shown to affect intracellular and circulating levels of lipids in diabetes (22, 25, 38), metabolic syndrome (39), and cardiovascular disease (40).”
BackgroundChazova, I. E., Almazov, V. A., & Shlyakhto, E. V. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00606.x · Cited by 74 · see citing works
Liang, B., Wang, S., Wang, Q., Zhang, W., Viollet, B., Zhu, Y., & Zou, M. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.112.300606 · Cited by 73 · see citing works
Adam, J., Brandmaier, S., Leonhardt, J., Scheerer, M. F., Mohney, R. P., Xu, T., Bi, J., Rotter, M., Troll, M., Chi, S., et al. (2016) · Diabetes · doi:10.2337/db16-0512 · Cited by 68 · see citing works
“, it reduces insulin resistance (2), improves the uptake of glucose in muscle (3,4), reduces the risk for cancer (5), and lowers the values of LDL cholesterol (LDL-C) (6).”
BackgroundPalumbo, P. J. (1998) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(97)00053-6 · Cited by 67 · see citing works
Gómez‐García, A., Torres, G. M., Ortega-Pierres, L. E., Rodríguez-Ayala, E., & Álvarez-Aguilar, C. (2007) · Revista Española de Cardiología · doi:10.1157/13113929 · Cited by 66 · see citing works
Metabolic effects of metformin in patients with impaired glucose tolerance
Lehtovirta, M., Forsén, B., Gullström, M., Häggblom, M. M., Eriksson, J. G., Taskinen, M., & Groop, L. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00539.x · Cited by 66 · see citing works
Han, X., Zhang, F., Meng, L., et al. (2019) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2019.110125 · Cited by 64 · see citing works
Acute Sympathoinhibitory Actions of Metformin in Spontaneously Hypertensive Rats
Petersen, J. S., & DiBona, G. F. (1996) · Hypertension · doi:10.1161/01.hyp.27.3.619 · Cited by 63 · see citing works
Metformin Therapy in Diabetes: The Role of Cardioprotection
Messaoudi, S. E., Rongen, G. A. P. J. M., & Riksen, N. P. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0314-z · Cited by 62 · see citing works
“Metformin seems to improve the lipid profile by lowering triglyceride levels, total cholesterol and LDL cholesterol levels, while maintaining or increasing HDL levels [37–42].”
BackgroundInsulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Checa, M. Á., Requena, A., Salvador, C., Tur, R., Callejo, J., Espinós, J. J., Fábregues, F., Herrero, J. C., & (Reproductive Endocrinology Interest Group of the Spanish Society of Fertility) (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi015 · Cited by 60 · see citing works
“Metformin has beneficial effects on serum lipid profiles in obese(Giugliano et al., 1993) and lean patients with non-insulin dependent diabetes mellitus, in other patients with type 2 diabetes and in patients with concomitant type 2 diabetes, hypertension and/or hyperlipidaemia (Landin et al.,…”
BackgroundMETFORMIN: NONGLYCEMIC EFFECTS AND POTENTIAL NOVEL INDICATIONS.
Anabtawi, A., & Miles, J. (2016) · Endocrine Practice · doi:10.4158/ep151145.ra · Cited by 51 · see citing works
Hormone replacement therapy and glucose tolerance in EPIC-Norfolk: a population-based study
Sargeant, L. A., Wareham, N. J., & Khaw, K. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200001/02)16:1 · Cited by 18 · see citing works
Rao, N. S., Pradeep, A. R., Kumari, M., et al. (2012) · Journal of Periodontology · doi:10.1902/jop.2012.120298 · Cited by 58 · see citing works
“It has also been shown that MF may be helpful in the fight against heart disease, kidney disease, decreased sexual ability and circulation problems.(5) Numerous studies have reported on the effects of this agent on bone turnover.”
BackgroundMoreno-Arriola, E., Hafidi, M. E., Ortega-Cuéllar, D., & Carvajal, K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148089 · Cited by 55 · see citing works
“Strikingly, we showed that in wild-type nematodes metformin prevented the effects generated by excess glucose intake, restoring the metabolic markers to control levels; similar to what occurs in obese and diabetic patients, where chronic metformin treatment decreases glucose and lipid levels in plasma [56].”
BackgroundEleftheriadou, I., Grigoropoulou, P., Katsilambros, N., & Tentolouris, N. (2008) · Current Diabetes Reviews · doi:10.2174/157339908786241133 · Cited by 55 · see citing works
“Some studies have shown that metformin reduces fasting plasma total cholesterol, total triglyceride and VLDL cholesterol concentrations and increases HDL cholesterol levels [48-51].”
BackgroundFontbonne, A., Diouf, I., Baccara-Dinet, M., Eschwege, E., & Charles, M.-A. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.03.005 · Cited by 53 · see citing works
Expression pattern of perilipins in human brain during aging and in Alzheimer's disease
Conte, M., Medici, V., Malagoli, D., Chiariello, A., Cirrincione, A., Davin, A., Chikhladze, M., Vasuri, F., Legname, G., Ferrer, I., et al. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12756 · Cited by 52 · see citing works
Bell, P. M., & Hadden, D. R. (1997) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(05)70265-6 · Cited by 51 · see citing works
MARTELL, N., RODRIGUEZ-CERRILLO, M., GROBBEE, D. E., LÓPEZ-EADY, M. D., FERNÁNDEZ-PINILLA, C., AVILA, M., FERNANDEZ-CRUZ, A., & LUQUE, M. (2003) · Blood Pressure · doi:10.1080/08037050310009950 · Cited by 49 · see citing works
“[32] reported similar results in a group of obese, no diabetic hypertensive women.”
ResultA Review on The Protective Effects of Metformin in Sepsis-Induced Organ Failure.
Hassan, F. I., Didari, T., Khan, F., Niaz, K., Mojtahedzadeh, M., & Abdollahi, M. R. (2020) · PubMed Central · doi:10.22074/cellj.2020.6286 · Cited by 48 · see citing works
“Metformin was shown to decrease blood pressure, left ventricular mass, and cholesterol, triglycerides, and fibrinogen levels in obese non-diabetic hypertensive women (41).”
BackgroundInsulin resistance and metformin in polycystic ovary syndrome
Ben‐Haroush, A., Yogev, Y., & Fisch, B. (2004) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2003.11.027 · Cited by 46 · see citing works
“In obese, nondiabetic women, metformin was found to decrease plasma cholesterol, triglyceride, and increase HDL-cholesterol concentrations, thereby, improving the lipoprotein profile and possibly reducing cardiovascular risk [67].”
BackgroundShishavan, M. H., Henning, R. H., van Buiten, A., Goris, M., Deelman, L. E., & Buikema, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-11430-7 · Cited by 48 · see citing works
“Some clinical studies have reported a blood pressure lowering effect of metformin [8-10] although others reported the lack of such effects [11-12].”
BackgroundKurian, I. G., Dileep, P., Ipshita, S., et al. (2018) · Journal of Investigative and Clinical Dentistry · doi:10.1111/jicd.12324 · Cited by 46 · see citing works
Insulin resistance in hypertension and cardiovascular disease
Lamounier‐Zepter, V., Ehrhart‐Bornstein, M., & Bornstein, S. R. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.002 · Cited by 45 · see citing works
Molusky, M. M., Hsieh, J., Lee, S. X., Ramakrishnan, R., Tascau, L., Haeusler, R. A., Accili, D., & Tall, A. R. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.118.311212 · Cited by 43 · see citing works
Differential Effects of Oral Hypoglycemic Agents on Glucose Control and Cardiovascular Risk
Uwaifo, G. I., & Ratner, R. E. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.006 · Cited by 43 · see citing works
Banek, C. T., Bauer, A. J., Needham, K. W., Dreyer, H. C., & Gilbert, J. S. (2013) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00903.2012 · Cited by 41 · see citing works
“Administration of an adenosine mimetics similar to AICAR, such as metformin, have long been recognized to improve cardiovascular function and lower blood pressure in nonpregnant hypertensives (20, 36), but the mechanisms remain uncharacterized (1, 19, 36, 38).”
BackgroundMetformin prevents vascular damage in hypertension through the AMPK/ER stress pathway
Chen, C., Kassan, A., Castañeda, D., Gabani, M. H., Choi, S. K., & Kassan, M. (2019) · Hypertension Research · doi:10.1038/s41440-019-0212-z · Cited by 40 · see citing works
Preventative effects of metformin on glucocorticoid-induced osteoporosis in rats
Zhao, J., Li, Y., Zhang, H., Shi, D., Li, Q., Meng, Y., & Zuo, L. (2019) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-019-00989-y · Cited by 40 · see citing works
Determination of Plasma Metformin by a New Cation-Exchange HPLC Technique
Bonfigli, A. R., Manfrini, S., Gregorio, F., et al. (1999) · Therapeutic Drug Monitoring · doi:10.1097/00007691-199906000-00015 · Cited by 40 · see citing works
Dorella, M., Giusto, M., Tos, V. D., Campagnolo, M., Palatini, P., Rossi, G., Ceolotto, G., Felice, M., Semplicini, A., & Prato, S. D. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.4.8636369 · Cited by 45 · see citing works
Attenuation of Hypertension by Insulin-Sensitizing Agents
Kotchen, T. A. (1996) · Hypertension · doi:10.1161/01.hyp.28.2.219 · Cited by 38 · see citing works
Metformin Treatment Improves Erectile Function in an Angiotensin II Model of Erectile Dysfunction
Labazi, H., Wynne, B. M., Tostes, R. C., & Webb, R. C. (2013) · The Journal of Sexual Medicine · doi:10.1111/jsm.12245 · Cited by 38 · see citing works
Stakos, D., Schuster, D. P., Sparks, E. A., Wooley, C. F., Osei, K., & Boudoulas, H. (2005) · Heart · doi:10.1136/hrt.2003.027722 · Cited by 37 · see citing works
Second World Congress on the Insulin Resistance Syndrome
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1821 · Cited by 37 · see citing works
Uehara, M. H., Kohlmann, N. E. B., Zanella, M. T., & Ferreira, S. R. G. (2001) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2001.00136.x · Cited by 38 · see citing works
Ji, S., Wang, L., & Li, L. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00704 · Cited by 37 · see citing works
“In patients with T2DM, who are also obese, metformin also plays a clinical role in obesity (5, 6).”
BackgroundCardiovascular Risk Factors Associated with Insulin Resistance: Effects of Oral Antidiabetic Agents
Granberry, M. C., & Fonseca, V. A. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00006 · Cited by 38 · see citing works
Palamara, K., Mogul, H. R., Peterson, S. J., & Frishman, W. H. (2006) · Cardiology in Review · doi:10.1097/01.crd.0000233903.57946.fd · Cited by 36 · see citing works
Effects of metformin on endothelial health and erectile dysfunction
Patel, J. P., Lee, E. H., Mena, C. I., & Walker, C. N. (2017) · Translational Andrology and Urology · doi:10.21037/tau.2017.03.52 · Cited by 33 · see citing works
Wulffelé, M. G., Kooy, A., de Zeeuw, D., Stehouwer, C. D. A., & Gansevoort, R. T. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.161311.x · Cited by 33 · see citing works
Grosskopf, I., Ringel, Y., Charach, G., Maharshak, N., Mor, R., Iaina, A., & Weintraub, M. S. (1997) · Diabetes Care · doi:10.2337/diacare.20.10.1598 · Cited by 32 · see citing works
Metformin Decreases Blood Pressure and Obesity in OLETF Rats Via Improvement of Insulin Resistance.
Kosegawa, I., Katayama, S., Kikuchi, C., Kashiwabara, H., Negishi, K., Ishii, J., Inukai, K., & Oka, Y. (1996) · Hypertension Research · doi:10.1291/hypres.19.37 · Cited by 33 · see citing works
Swislocki, A., Eason, T., & Kaysen, G. A. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00161-1 · Cited by 33 · see citing works
Lim, E., Park, S., & Kim, H. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4899-0117-0_13 · Cited by 32 · see citing works
Muntzel, M. S., Abe, A., & Petersen, J. S. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36647-9 · Cited by 31 · see citing works
Oleandri, S. E., Maccario, M., Rossetto, R., Massimo, P., Grottoli, S., Avogadri, E., Gauna, C., Ganzaroli, C., & Ghigo, E. (1999) · Journal of Endocrinological Investigation · doi:10.1007/bf03350893 · Cited by 31 · see citing works
Stümvoll, M., Häring, H., & Matthaei, S. (2007) · Endocrine Research · doi:10.1080/07435800701743828 · Cited by 31 · see citing works
Wulffelé, M. G., Kooy, A., Lehert, P., Bets, D., Donker, A. J. M., & Stehouwer, C. D. A. (2005) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01554.x · Cited by 30 · see citing works
Impact of non-antibiotic drugs on the human intestinal microbiome
Bastard, Q. L., Berthelot, L., Soulillou, J., & Montassier, E. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1952075 · Cited by 30 · see citing works
- Authors
- Giugliano, D., De Rosa, N., Di Maro, G., Marfella, R., Acampora, R., Buoninconti, R., & D'Onofrio, F.
- Affiliations
- University of Campania "Luigi Vanvitelli" (IT)
- Department of Gerontology and Metabolic Diseases, Second University of Naples Naples, Italy
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1993-10-01
- Volume
- 16
- Issue
- 10
- Pages
- 1387-1390
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2039851346
- Cited by
- 206
- References
- 0
- Citations by year
- 2026: 1 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 9 · 2018: 9 · 2017: 10 · 2016: 8 · 2015: 8 · 2014: 6 · 2013: 10 · 2012: 3
- FWCI
- 5.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- metformin, hypertension, obesity, women, glucose metabolism, insulin sensitivity, blood pressure, left ventricular mass, lipid metabolism, cardiovascular risk, non-diabetic patients, fibrinogen, HDL cholesterol
- MeSH terms
- Blood Glucose, Blood Pressure, Calorimetry, Cholesterol, Double-Blind Method, Echocardiography, Female, Fibrinogen, Glucose Tolerance Test, Glycated Hemoglobin, Humans, Hypertension, Insulin, Metformin, Middle Aged, Obesity, Triglycerides, Glucose Clamp Technique
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
